vs

Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $17.6M, roughly 1.6× AVITA Medical, Inc.). AVITA Medical, Inc. runs the higher net margin — -66.0% vs -125.8%, a 59.8% gap on every dollar of revenue. On growth, Creative Media & Community Trust Corp posted the faster year-over-year revenue change (3.6% vs -4.3%). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs -8.5%).

Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

CMCT vs RCEL — Head-to-Head

Bigger by revenue
CMCT
CMCT
1.6× larger
CMCT
$28.5M
$17.6M
RCEL
Growing faster (revenue YoY)
CMCT
CMCT
+7.9% gap
CMCT
3.6%
-4.3%
RCEL
Higher net margin
RCEL
RCEL
59.8% more per $
RCEL
-66.0%
-125.8%
CMCT
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
-8.5%
CMCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CMCT
CMCT
RCEL
RCEL
Revenue
$28.5M
$17.6M
Net Profit
$-11.4M
$-11.6M
Gross Margin
81.2%
Operating Margin
-125.6%
-59.1%
Net Margin
-125.8%
-66.0%
Revenue YoY
3.6%
-4.3%
Net Profit YoY
-11.4%
-0.3%
EPS (diluted)
$-3.89
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMCT
CMCT
RCEL
RCEL
Q4 25
$28.5M
$17.6M
Q3 25
$26.2M
$17.1M
Q2 25
$29.7M
$18.4M
Q1 25
$32.3M
$18.5M
Q4 24
$27.5M
$18.4M
Q3 24
$28.6M
$19.5M
Q2 24
$34.4M
$15.2M
Q1 24
$34.0M
$11.1M
Net Profit
CMCT
CMCT
RCEL
RCEL
Q4 25
$-11.4M
$-11.6M
Q3 25
$-12.5M
$-13.2M
Q2 25
$-9.0M
$-9.9M
Q1 25
$-6.1M
$-13.9M
Q4 24
$-10.3M
$-11.6M
Q3 24
$-10.4M
$-16.2M
Q2 24
$-796.0K
$-15.4M
Q1 24
$-3.7M
$-18.7M
Gross Margin
CMCT
CMCT
RCEL
RCEL
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
CMCT
CMCT
RCEL
RCEL
Q4 25
-125.6%
-59.1%
Q3 25
-47.7%
-53.6%
Q2 25
-30.3%
-60.5%
Q1 25
-19.0%
-63.9%
Q4 24
-128.8%
-54.1%
Q3 24
-36.9%
-70.6%
Q2 24
-1.6%
-102.8%
Q1 24
-10.7%
-155.0%
Net Margin
CMCT
CMCT
RCEL
RCEL
Q4 25
-125.8%
-66.0%
Q3 25
-47.5%
-77.3%
Q2 25
-30.3%
-53.9%
Q1 25
-18.9%
-74.9%
Q4 24
-129.8%
-63.0%
Q3 24
-36.3%
-82.9%
Q2 24
-2.3%
-101.3%
Q1 24
-11.0%
-168.0%
EPS (diluted)
CMCT
CMCT
RCEL
RCEL
Q4 25
$-3.89
$-0.37
Q3 25
$-23.52
$-0.46
Q2 25
$-18.94
$-0.38
Q1 25
$-20.73
$-0.53
Q4 24
$97.71
$-0.44
Q3 24
$-305.04
$-0.62
Q2 24
$-98.64
$-0.60
Q1 24
$-125.46
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMCT
CMCT
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$15.4M
$18.2M
Total DebtLower is stronger
$509.8M
Stockholders' EquityBook value
$265.4M
$-16.6M
Total Assets
$859.2M
$56.4M
Debt / EquityLower = less leverage
1.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMCT
CMCT
RCEL
RCEL
Q4 25
$15.4M
$18.2M
Q3 25
$17.3M
$23.3M
Q2 25
$27.8M
$15.7M
Q1 25
$19.8M
$25.8M
Q4 24
$20.3M
$35.9M
Q3 24
$18.5M
$44.4M
Q2 24
$29.3M
$54.1M
Q1 24
$21.3M
$68.2M
Total Debt
CMCT
CMCT
RCEL
RCEL
Q4 25
$509.8M
Q3 25
$527.8M
Q2 25
$535.6M
Q1 25
$512.7M
Q4 24
$505.7M
Q3 24
$478.3M
Q2 24
$485.1M
Q1 24
$472.8M
Stockholders' Equity
CMCT
CMCT
RCEL
RCEL
Q4 25
$265.4M
$-16.6M
Q3 25
$281.9M
$-6.7M
Q2 25
$287.1M
$-12.9M
Q1 25
$293.0M
$-4.6M
Q4 24
$304.5M
$4.5M
Q3 24
$321.0M
$12.2M
Q2 24
$351.1M
$23.9M
Q1 24
$369.9M
$32.6M
Total Assets
CMCT
CMCT
RCEL
RCEL
Q4 25
$859.2M
$56.4M
Q3 25
$871.8M
$63.7M
Q2 25
$885.0M
$58.1M
Q1 25
$882.3M
$69.6M
Q4 24
$889.6M
$79.7M
Q3 24
$868.0M
$81.1M
Q2 24
$891.2M
$87.8M
Q1 24
$887.5M
$97.4M
Debt / Equity
CMCT
CMCT
RCEL
RCEL
Q4 25
1.92×
Q3 25
1.87×
Q2 25
1.87×
Q1 25
1.75×
Q4 24
1.66×
Q3 24
1.49×
Q2 24
1.38×
Q1 24
1.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMCT
CMCT
RCEL
RCEL
Operating Cash FlowLast quarter
$5.8M
$-5.4M
Free Cash FlowOCF − Capex
$-6.1M
FCF MarginFCF / Revenue
-34.7%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMCT
CMCT
RCEL
RCEL
Q4 25
$5.8M
$-5.4M
Q3 25
$3.7M
$-5.2M
Q2 25
$-2.5M
$-10.2M
Q1 25
$1.2M
$-10.3M
Q4 24
$17.0M
$-8.1M
Q3 24
$10.3M
$-7.2M
Q2 24
$3.9M
$-12.8M
Q1 24
$1.6M
$-20.9M
Free Cash Flow
CMCT
CMCT
RCEL
RCEL
Q4 25
$-6.1M
Q3 25
$-6.2M
Q2 25
$-10.8M
Q1 25
$-10.5M
Q4 24
$-9.7M
Q3 24
$-11.0M
Q2 24
$-15.4M
Q1 24
$-22.0M
FCF Margin
CMCT
CMCT
RCEL
RCEL
Q4 25
-34.7%
Q3 25
-36.1%
Q2 25
-58.4%
Q1 25
-56.9%
Q4 24
-52.7%
Q3 24
-56.1%
Q2 24
-101.6%
Q1 24
-198.2%
Capex Intensity
CMCT
CMCT
RCEL
RCEL
Q4 25
3.8%
Q3 25
5.5%
Q2 25
2.8%
Q1 25
1.2%
Q4 24
8.8%
Q3 24
19.2%
Q2 24
17.5%
Q1 24
10.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons